NEW ZEALAND DATA SHEET

1 PRODUCT NAME
ZOMET® 4 mg/5 mL Liquid Concentrate for Solution for Infusion and 4 mg powder and solvent for solution for infusion.*

2 QUALITATIVE AND QUANTITATIVE COMPOSITION
One vial with 5 mL concentrate contains 4 mg zoledronic acid (anhydrous), corresponding to 4.264 mg zoledronic acid monohydrate.
One vial contains 4 mg zoledronic acid (anhydrous), corresponding to 4.264 mg zoledronic acid monohydrate.*
For a full list of excipients, see section 6.1 List of excipients.

3. PHARMACEUTICAL FORM
Concentrate for solution for infusion.
Powder and solvent for solution for infusion.*

4. CLINICAL PARTICULARS
4.1 Therapeutic indications
Adults
- Prevention of skeletal-related events (pathological fracture, spinal cord compression, radiation to bone or surgery to bone) in patients with advanced malignancies involving bone.
- Treatment of tumour-induced hypercalcemia.

4.2 Posology and method of administration
Zomet® must not be mixed with calcium or other divalent cation-containing infusion solutions, such as Lactated Ringer’s solution, and should be administered as a single intravenous solution in a line separate from all other drugs.

Prevention of skeletal related events in patients with advanced malignancies involving bone
In adults and elderly patients the recommended dose in the prevention of skeletal related events in patients with advanced malignancies involving bone is 4 mg zoledronic acid. The concentrate must be further diluted with 100 mL 0.9% w/v sodium chloride or 5% w/v glucose solution, and given as an intravenous infusion lasting no less than 15 minutes every 3 to 4 weeks.
The powder* should be reconstituted in the vial using 5 mL water for injection from the supplied ampoule. The reconstituted solution should be further diluted with 100 mL 0.9% w/v sodium chloride or 5% w/v glucose solution before infusion (see Pharmaceutical
information/Instructions for use and handling). The final Zometa solution for infusion, should be given as an intravenous infusion in no less than 15 minutes.

Patients should also be administered an oral calcium supplement of 500 mg and 400 IU vitamin D daily.

**Treatment of tumour-induced hypercalcemia (TIH)**

In adults and elderly patients the recommended dose in hypercalcemia (albumin-corrected serum calcium ≥12.0 mg/dL or 3.0 mmol/L) is 4 mg zoledronic acid. The concentrate must be further diluted with 100 mL 0.9% w/v sodium chloride or 5% w/v glucose solution, given as a single intravenous infusion of no less than 15 minutes. Patients must be maintained well hydrated prior to and following administration of Zometa.

**Treatment of patients with renal impairment**

**Treatment of patients with tumour-induced hypercalcemia (TIH)**

Zometa treatment in adult patients with tumour-induced hypercalcemia (TIH) and who have severe renal impairment should be considered only after evaluating the risks and benefit of treatment. In the clinical studies, patients with serum creatinine >400 micromol/L or >4.5 mg/dL were excluded. No dose adjustment is necessary in TIH patients with serum creatinine <400 micromol/L or <4.5 mg/dL (see Warnings and precautions).

**Patients with advanced malignancy involving bone and other patients**

When initiating treatment with Zometa in adult patients with multiple myeloma or metastatic bone lesions from solid tumours, serum creatinine levels and creatinine clearance (CLcr) should be determined. CLcr is calculated from serum creatinine levels using the Cockcroft-Gault formula. Zometa is not recommended for patients presenting with severe renal impairment prior to initiation of therapy, which is defined for this population as CLcr <30 mL/min. In clinical trials with Zometa, patients with serum creatinine >265 micromol/L or >3.0 mg/dL were excluded.

In patients with bone metastases presenting with mild to moderate renal impairment prior to initiation of therapy, which is defined for this population as CLcr 30 to 60 mL/min, the following Zometa dose is recommended (see also Warnings and precautions):

<table>
<thead>
<tr>
<th>Baseline Creatinine Clearance (mL/min)</th>
<th>Zometa Recommended Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;60</td>
<td>4.0 mg</td>
</tr>
<tr>
<td>50 - 60</td>
<td>3.5 mg*</td>
</tr>
<tr>
<td>40 - 49</td>
<td>3.3 mg*</td>
</tr>
<tr>
<td>30 - 39</td>
<td>3.0 mg*</td>
</tr>
</tbody>
</table>

*Doses have been calculated assuming target AUC of 0.66 (mg•hr/L) (CLcr=75mL/min). The reduced doses for patients with renal impairment are expected to achieve the same AUC as that seen in patients with creatinine clearance of 75 mL/min.*

Following initiation of therapy, serum creatinine should be measured prior to each dose of Zometa and treatment should be withheld if renal function has deteriorated. In the clinical trials, renal deterioration was defined as follows:
For patients with normal baseline serum creatinine (<1.4 mg/dL), an increase of ≥0.5 mg/dL;
For patients with an abnormal baseline creatinine (>1.4 mg/dL), an increase of ≥1.0 mg/dL.

In the clinical studies, Zometa treatment was resumed only when the creatinine level returned to within 10% of the baseline value (see Warnings and precautions). Zometa should be resumed at the same dose as that prior to treatment interruption.

**Paediatric Population**

The safety and efficacy of zoledronic acid in children aged 1 year to 17 years have not been established.

**Method of administration**

Zometa must only be administered to patients by healthcare professionals experienced in the administration of intravenous bisphosphonates.

Zometa must not be mixed with calcium or other divalent cation-containing infusion solutions, such as Lactated Ringer’s solution, and should be administered as a single intravenous solution in a line separate from all other drugs in no less than 15 minutes.

Patients must be maintained in a well hydrated state prior to and following administration of Zometa.

**Preparation of reduced Zometa doses**

In patients with mild to moderate renal impairment, which is defined as CLcr 30 to 60 mL/min, reduced Zometa dosages are recommended, except in patients with TH (see Dosage and administration).

To prepare reduced doses of Zometa® 4 mg powder* or Zometa® 4 mg/5 mL concentrate withdraw an appropriate volume of the liquid concentrate needed, as follows:

- 4.4 mL for 3.5 mg dose
- 4.1 mL for 3.3 mg dose
- 3.8 mL for 3.0 mg dose

The withdrawn amount of liquid concentrate must be further diluted in 100 mL of sterile 0.9% w/v sodium chloride solution or 5% w/v glucose solution. The dose must be given as a single intravenous infusion of no less than 15 minutes.

**4.3 Contraindications**

Zometa concentrate is contraindicated in pregnancy and breast-feeding women. Hypersensitivity to zoledronic acid or other bisphosphonates or any of the excipients in the formulation of Zometa.
4.4 Special warnings and precautions for use

General

All patients, including paediatric patients and patients with mild to moderate renal impairment, must be assessed prior to administration of Zometa to assure that they are adequately hydrated.

Overhydration should be avoided in patients at risk of cardiac failure.

Standard hypercalcemia-related metabolic parameters, such as albumin-corrected serum levels of calcium, phosphate and magnesium as well as serum creatinine should be carefully monitored after initiating Zometa therapy. If hypocalcemia, hypophosphatemia, or hypomagnesemia occur, short-term supplemental therapy may be necessary. Untreated hypercalcemia patients generally have some degree of renal function impairment, therefore careful renal function monitoring should be considered.

Zometa contains the same active ingredient as in Aclasta (zoledronic acid). Patients being treated with Zometa should not be treated with Aclasta concomitantly. Zometa should also not be given together with other bisphosphonates since the combined effects of these agents are unknown.

While not observed in clinical trials with Zometa, there have been reports of bronchoconstriction in acetylsalicylic acid sensitive asthmatic patients receiving bisphosphonates.

Paediatric Population

The safety and efficacy of Zometa in paediatric patients have not been established.

Renal impairment

Adult patients with TIH and evidence of deterioration in renal function should be appropriately evaluated with consideration given as to whether the potential benefit of continued treatment with Zometa outweighs the possible risk (see Dosage and Administration).

The decision to treat patients with bone metastases for the prevention of skeletal related events should consider that the onset of treatment effect is 2 to 3 months.

Bisphosphonates have been associated with reports of renal dysfunction. Factors that may increase the potential for deterioration in renal function include dehydration, pre-existing renal impairment, multiple cycles of Zometa or other bisphosphonates as well as use of nephrotoxic drugs or using a shorter infusion time than currently recommended. While the risk is reduced with a dose of Zometa 4 mg administered over no less than 15 minutes, deterioration in renal function may still occur. Renal deterioration, progression to renal failure and dialysis have been reported in patients after the initial dose or a single dose of Zometa. Increases in serum creatinine also occur in some patients with chronic administration of Zometa at recommended doses for prevention of skeletal related events, although less frequently.

Serum creatinine levels should be measured before each Zometa dose. In patients with bone metastases with mild to moderate renal impairment at initiation of Zometa treatment, lower
doses are recommended in all patients except patients with TIH. In patients who show evidence of renal deterioration during treatment, Zometa should only be resumed when creatinine level returns to within 10% of baseline value (see Dosage and administration).

The use of Zometa is not recommended in patients with severe renal impairment because there are limited clinical safety and pharmacokinetic data in this population, and there is a risk of renal function deterioration in patients treated with bisphosphonates, including Zometa. In clinical trials, patients with severe renal impairment were defined as those with baseline serum creatinine ≥400 micromol/L or ≥4.5 mg/dL for patients with TIH and ≥265 micromol/L or ≥3.0 mg/dL for patients with cancer and bone metastases respectively. In pharmacokinetic studies, patients with severe renal impairment were defined as those with baseline creatinine clearance <30 mL/min (see Pharmacokinetics and Dosage and Administration).

The safety of Zometa in paediatric patients with renal impairment has not been established.

**Hepatic insufficiency**

As only limited clinical data are available in patients with severe hepatic insufficiency, no specific recommendations can be given for this patient population.

**Osteonecrosis**

**Osteonecrosis of the jaw**

Osteonecrosis of the jaw (ONJ) has been reported predominantly in adult cancer patients treated with bisphosphonates, including Zometa. Many of these patients were also receiving chemotherapy and corticosteroids. Many had signs of local infection including osteomyelitis.

Post-marketing experience and the literature suggest a greater frequency of reports of ONJ based on tumour type (advanced breast cancer, multiple myeloma), and dental status (dental extraction, periodontal disease, local trauma including poorly fitting dentures).

Patients should maintain good oral hygiene and should have a dental examination with preventive dentistry prior to treatment with bisphosphonates.

While on treatment with bisphosphonates, patients should avoid invasive dental procedures if possible. For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy, dental surgery may exacerbate the condition. For patients requiring dental procedures, there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk of osteonecrosis of the jaw. Clinical judgment of the treating physician should guide the management plan of each patient based on individual benefit/risk assessment.

**Osteonecrosis of other anatomical sites**

Cases of osteonecrosis of other anatomical sites including the hip, femur and external auditory canal have been reported predominantly in adult cancer patients treated with bisphosphonates, including Zometa.

**Atypical fractures of the femur**

Atypical subtrochanteric and diaphyseal femoral fractures have been reported in patients receiving bisphosphonate therapy, primarily in patients receiving long-term treatment for osteoporosis. These transverse or short oblique fractures can occur anywhere along the femur.
from just below the lesser trochanter to just above the supracondylar flare. These fractures occur after minimal or no trauma and some patients experience thigh or groin pain, often associated with imaging features of stress fractures, weeks to months before presenting with a completed femoral fracture. Fractures are often bilateral; therefore the contralateral femur should be examined in Zometa-treated patients, who have sustained a femoral shaft fracture. Poor healing of these fractures has also been reported. Discontinuation of Zometa therapy in patients suspected to have an atypical femur fracture should be considered pending evaluation of the patient, based on an individual benefit risk assessment. Reports of atypical femoral fracture have been received in patients treated with Zometa; however causality with Zometa therapy has not been established.

During Zometa treatment patients should be advised to report any thigh, hip or groin pain and any patient presenting with such symptoms should be evaluated for an incomplete femur fracture.

Musculoskeletal pain

In post-marketing experience, severe and occasionally incapacitating bone, joint, and/or muscle pain have been reported in patients taking bisphosphonates, including Zometa (see Adverse Effects). The time to onset of symptoms varied from one day to several months after starting treatment. Most patients had relief of symptoms after stopping treatment. A subset had recurrence of symptoms when re-challenged with the same drug or another bisphosphonate.

Zometa contains the same active ingredient as found in Aclasta (zoledronic acid). Patients being treated with Zometa should not be treated with Aclasta concomitantly.

Hypocalcemia

Hypocalcemia has been reported in patients treated with Zometa. Cardiac arrhythmias and neurologic adverse events (seizures, tetany, and numbness) have been reported secondary to cases of severe hypocalcemia. In some instances, the hypocalcemia may be life-threatening. Caution is advised when Zometa is administered with other hypocalcemia causing drugs, as they may have synergistic effect resulting in severe hypocalcemia (see Interactions with Other Medicines). Serum calcium should be measured and hypocalcemia must be corrected before initiating Zometa therapy. Patients should be adequately supplemented with calcium and vitamin D.

4.5 Interaction with other medicinal products and other forms of interaction

Anticipated interactions to be considered

Caution is advised when bisphosphonates like Zometa are administered with aminoglycosides or calcitonin or loop diuretics, since these agents may have an additive effect, resulting in a lower serum calcium level for longer periods than required (see Warnings and precautions).

Caution is indicated when Zometa is used with other potentially nephrotoxic drugs.

Observed interactions to be considered

Caution is advised when Zometa is administered with anti-angiogenic drugs as an increase in incidence of ONJ have been observed in patients treated concomitantly with these drugs.
Absence of interactions

In clinical studies, Zometa has been administered concomitantly with commonly used anticancer agents, diuretics (except for loop diuretics, see Anticipated interactions to be considered), antibiotics and analgesics without clinically apparent interactions occurring.

No dose adjustment for Zometa is needed when co-administered with thalidomide, except in patients with mild to moderate renal impairment at baseline (see Dosage and administration). Co-administration of thalidomide (100 mg once daily) with Zometa (4 mg given as a 15 minute infusion) did not significantly change the pharmacokinetics of zoledronic acid and the creatinine clearance of patients with multiple myeloma.

4.6 Fertility, pregnancy and lactation

Women of child-bearing potential

Women of child-bearing potential should be advised to avoid becoming pregnant and advised of the potential hazard to the fetus while receiving Zometa. There may be a risk of fetal harm (e.g. skeletal and other abnormalities) if a woman becomes pregnant while receiving bisphosphonate therapy. The impact of variables such as time between cessation of bisphosphonate therapy to conception, the particular bisphosphonate used, and the route of administration on this risk has not been established.

Pregnancy

In animal reproduction studies zoledronic acid was administered subcutaneously to rats and rabbits. It was found to be teratogenic at doses ≥0.2 mg/kg bodyweight in rats. In rabbits, there was no teratogenicity or foeto-toxicity but maternotoxicity was found. Zometa should not be used during pregnancy (see Contraindications).

Breast-feeding

It is not known whether zoledronic acid is excreted into human milk. Zometa should not be used by breast-feeding women (see Contraindications).

4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed.

4.8 Undesirable effects

Summary of the safety profile

The most serious adverse drug reactions reported in patients receiving Zometa in the approved indications are: anaphylactic reaction, ocular adverse events, osteonecrosis of the jaw, atypical femoral fracture, atrial fibrillation, renal function impairment, acute phase reaction, and hypocalcemia. The frequencies of these adverse reactions are shown in Table 1 or shown as adverse reactions from ‘Spontaneous reports and literature cases’ with “not known” frequency.

Frequencies of adverse reactions for Zometa 4 mg are mainly based on data collected from chronic treatment. Adverse reactions to Zometa are usually mild and transient and similar to those reported for other bisphosphonates. Those reactions can be expected to occur in
approximately one third of patients treated with Zometa. Intravenous administration has been most commonly associated with a flu-like illness including bone pain, arthritis with subsequent joint swelling, fever, fatigue and rigors. Cases of arthralgia and myalgia have commonly been reported.

Very commonly, the reduction in renal calcium excretion is accompanied by a fall in serum phosphate levels, which is asymptomatic not requiring treatment. Commonly, the serum calcium may fall to asymptomatic hypocalcemic levels.

Gastrointestinal reactions, such as nausea and vomiting have been reported following intravenous infusion of Zometa. Uncommonly local reactions at the infusion site such as redness or swelling and/or pain were also observed.

Anorexia was commonly reported in patients treated with Zometa 4 mg.

Rash or pruritus has been uncommonly observed.

As with other bisphosphonates, cases of conjunctivitis have been commonly reported.

Reports of impaired renal function in clinical trials in postmenopausal women with early breast cancer treated with aromatase inhibitors were 0.2%. Based on pooled analysis of placebo controlled studies, severe anaemia (Hb <8.0 g/dL) was reported in 5.2% of patients receiving Zometa 4 mg versus 4.2% on placebo.

Based on pooled analysis of placebo controlled studies, severe anemia (Hb < 8.0 g/dL) was commonly reported in patients receiving Zometa 4 mg.

Adverse drug reactions from clinical studies (Table 1) are listed by MedDRA system organ class. Within each system organ class, the adverse drug reactions are ranked under headings of frequency, the most frequent first. Within each frequency grouping, adverse drug reactions are presented in order of decreasing seriousness. In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention (CIOMS): Very common (≥1/10), common (≥1/100, < 1/10), uncommon (≥1/1,000, <1/100), rare (≥1/10,000, <1/1,000), very rare (<1/10,000).

<table>
<thead>
<tr>
<th>Table 1: Adverse drug reactions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Blood and lymphatic system disorders</strong></td>
</tr>
<tr>
<td>Common: Anemia.</td>
</tr>
<tr>
<td>Uncommon: Thrombocytopenia, leukopenia.</td>
</tr>
<tr>
<td>Rare: Pancytopenia.</td>
</tr>
</tbody>
</table>

| **Nervous system disorders** |
| Common: Headache, paresthesia. |
| Uncommon: Dizziness, dysgeusia, hypoesthesia, hyperesthesia, tremor. |
| Very rare: Convulsion, hypoesthesia and tetany (secondary to hypocalcemia) |

| **Psychiatric disorders** |
| Common: Sleep disorder |
| Uncommon: Anxiety. |
| Rare: Confusional state |

| **Eye disorders** |
| Common: Conjunctivitis. |
| Uncommon: Blurred Vision. |
Rare: Uveitis, episcleritis.

**Gastrointestinal disorders**
- **Common:** Nausea, vomiting, decreased appetite, constipation.
- **Uncommon:** Diarrhea, abdominal pain, dyspepsia, stomatitis, dry mouth.

**Respiratory, thoracic and mediastinal disorders:**
- **Uncommon:** Dyspnoea, cough
- **Rare:** Interstitial lung disease (ILD)

**Skin and subcutaneous tissue disorders**
- **Common:** Hyperhidrosis
- **Uncommon:** Pruritus, rash (including erythematous and macular rash).

**Musculoskeletal, connective tissue and bone disorders**
- **Common:** Bone pain, myalgia, arthralgia, generalised pain, joint stiffness.
- **Uncommon:** Osteonecrosis of jaw (ONJ), muscle spasms

**Cardiac disorders**
- **Rare:** Bradycardia, cardiac arrhythmia (secondary to hypocalcemia).

**Vascular disorders**
- **Common:** Hypertension
- **Uncommon:** Hypotension

**Renal and urinary disorders**
- **Common:** Renal impairment.
- **Uncommon:** Acute renal failure, haematuria, proteinuria.
- **Rare:** Acquired Fanconi syndrome

**Immune system disorders**
- **Uncommon:** Hypersensitivity reaction.
- **Rare:** Angioedema.

**General disorders and administration site conditions**
- **Common:** Acute phase reaction, fever, flu-like syndrome (including: fatigue, rigors, malaise and flushing), peripheral oedema, asthenia
- **Uncommon:** Injection site reactions (including: pain, irritation, swelling, induration, redness), chest pain, weight increased
- **Rare:** Arthritis and joint swelling as a symptom of Acute phase reaction.

**Investigations**
- **Very common:** Hypophosphatemia.
- **Common:** Blood creatinine and blood urea increased, hypocalcemia.
- **Uncommon:** Hypomagnesemia, hypokalemia.
- **Rare:** Hyperkalemia, hypernatremia.

---

**Adverse drug reactions from spontaneous reports and literature cases (frequency not known)**

The following adverse reactions have been reported during post-marketing experience with Zometa via spontaneous case reports and literature cases. Because these reactions are reported voluntarily from a population of uncertain size and are subject to confounding factors, it is not possible to reliably estimate their frequency (which is therefore categorized as not known) or establish a causal relationship to drug exposure.

**Immune system disorders:** anaphylactic reaction/shock
Nervous system disorders: somnolence

Eye disorders: episcleritis, scleritis and orbital inflammation

Cardiac disorders: atrial fibrillation

Vascular disorders: hypotension leading to syncope or circulatory collapse, primarily in patients with underlying risk factors

Respiratory, thoracic and mediastinal disorders: bronchospasms

Skin and subcutaneous tissue disorders: urticaria

Musculoskeletal and connective tissue disorders: severe and occasionally incapacitating bone, joint, and/or muscle pain, atypical subtrochanteric and diaphyseal femoral fractures (bisphosphonate class adverse reaction, including Zometa).

Description of selected adverse reactions

Renal function impairment

Zometa has been associated with reports of renal function impairment. In a pooled analysis of safety data from Zometa registration trials for the prevention of skeletal-related events in patients with advanced malignancy involving bone, the frequency of renal function impairment adverse events suspected to be related to Zometa (adverse reactions) was as follows: multiple myeloma (3.2%), prostate cancer (3.1%), breast cancer (4.3%), lung and other solid tumours (3.2%). Factors that may increase the potential for deterioration in renal function include dehydration, pre-existing renal impairment, multiple cycles of Zometa or other bisphosphonates, as well as concomitant use of nephrotoxic medicinal products or using a shorter infusion time than currently recommended. Renal deterioration, progression to renal failure and dialysis have been reported in patients after the initial dose or a single dose of Zometa (see Warnings and precautions).

Osteonecrosis

Cases of osteonecrosis (primarily of the jaw but also of other anatomical sites including hip, femur and external auditory canal) have been reported predominantly in cancer patients treated with bisphosphonates, including Zometa. Many patients with osteonecrosis of the jaw had signs of local infection including osteomyelitis, and the majority of the reports refer to cancer patients following tooth extractions or other dental surgeries. Osteonecrosis of the jaws has multiple well documented risk factors including a diagnosis of cancer, concomitant therapies (e.g. chemotherapy, anti-angiogenic drugs, radiotherapy, corticosteroids) and co-morbid conditions (e.g. anaemia, coagulopathies, infection, pre-existing oral disease). Although causality has not been determined, it is prudent to avoid dental surgery as recovery may be prolonged (see Warnings and precautions). Data suggests a greater frequency of reports of ONJ based on tumour type (advanced breast cancer, multiple myeloma).

Acute phase reaction

This adverse drug reaction consists of a constellation of symptoms that includes pyrexia, fatigue, bone pain, chills, influenza-like illness, arthritis with subsequent joint swelling. The onset time is ≤ 3 days post-Zometa infusion, and the reaction is also referred to using the terms “flu-like” or “post-dose” symptoms; these symptoms usually resolve within a few days.

Atrial fibrillation
In one 3 year, randomised, double-blind controlled trial that evaluated the efficacy and safety of zoledronic acid 5 mg once yearly vs placebo in the treatment of postmenopausal osteoporosis (PMO), the overall incidence of atrial fibrillation was 2.5% (96 out of 3,862) and 1.9% (75 out of 3,852) in patients receiving zoledronic acid 5 mg and placebo, respectively. The rate of atrial fibrillation serious adverse events was 1.3% (51 out of 3,862) and 0.6% (22 out of 3,852) in patients receiving zoledronic acid 5 mg and placebo, respectively. The imbalance observed in this trial has not been observed in other trials with zoledronic acid, including those with Zometa (zoledronic acid) 4 mg every 3 to 4 weeks in oncology patients. The mechanism behind the increased incidence of atrial fibrillation in this single clinical trial is unknown.

4.9 Overdose

Clinical experience with acute overdosage of Zometa is limited. Patients who have received doses higher than those recommended should be carefully monitored, since renal function impairment (including renal failure) and serum electrolyte (including calcium, phosphorus and magnesium) abnormalities have been observed. In the event of hypocalcemia, calcium gluconate infusions should be administered as clinically indicated.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Bisphosphonate, ATC code: M05 BA08

Mechanism of action

Zoledronic acid is a highly potent drug that belongs to the bisphosphonate class of drugs, which act primarily on bone. It is one of the most potent inhibitors of osteoclastic bone resorption known to date.

The selective action of bisphosphonates on bone is based on their high affinity for mineralised bone, but the precise molecular mechanism leading to the inhibition of osteoclastic activity is still unclear. In long-term animal studies, zoledronic acid inhibits bone resorption without adversely affecting the formation, mineralization or mechanical properties of bone.

In addition to being a very potent inhibitor of bone resorption, zoledronic acid also possesses several anti-tumour properties that could contribute to its overall efficacy in the treatment of metastatic bone disease. The following properties have been demonstrated in preclinical studies:

In vivo: Inhibition of osteoclastic bone resorption, which alters the bone marrow microenvironment making it less conducive to tumour cell growth, anti-angiogenic activity, anti-pain activity.

In vitro: Inhibition of osteoblast proliferation, direct cytostatic and pro-apoptotic activity on tumour cells, synergistic cytostatic effect with other anti-cancer drugs, anti-adhesion/invasion activity.

CLINICAL STUDIES
Clinical trial results in the prevention of skeletal related events in patients with advanced malignancies involving bone

Zometa was compared to placebo for the prevention of skeletal related events (SREs) in adult prostate cancer patients with 214 men receiving Zometa 4 mg versus 208 receiving placebo. After the initial 15 months of treatment, 186 patients continued for up to an additional 9 months, giving a total duration of double-blind therapy up to 24 months. Zometa 4 mg demonstrated a significant advantage over placebo for the proportion of patients experiencing at least one skeletal related event (SRE) (38% for Zometa 4 mg versus 49% for placebo, p=0.028), delayed the median time to first SRE (488 days for Zometa 4 mg versus 321 days for placebo, p=0.009), and reduced the annual incidence of event per patient - skeletal morbidity rate (0.77 for Zometa 4 mg versus 1.47 for placebo, p=0.005). Multiple event analysis showed 36% risk reduction in developing skeletal related events in the Zometa group compared with placebo (p=0.002). Pain was measured at baseline and periodically throughout the trial. Patients receiving Zometa reported less increase in pain than those receiving placebo, and the differences reached significance at months 3, 9, 21 and 24. Fewer Zometa patients suffered pathological fractures. The treatment effects were less pronounced in patients with blastic lesions. Efficacy results are provided in Table 2.

In a second study, Zometa reduced the number of SREs and extended the median time to an SRE by over two months in the population of adult patients who had other solid tumours involving bone, which had a median survival of only six months (134 patients with non-small-cell lung cancer [NSCLC], 123 with other solid tumours treated with Zometa vs 130 patients with NSCLC, 120 with other solid tumours treated with placebo). After initial 9 months of treatment, 101 patients entered the 12 month extension study, and 26 completed the full 21 months. Zometa 4 mg reduced the proportion of patients with SREs (39% for Zometa 4 mg versus 48% for placebo, p=0.039), delayed the median time to first SRE (236 days for Zometa 4 mg versus 155 days for placebo, p=0.009), and reduced the annual incidence of events per patient - skeletal morbidity rate (1.74 for Zometa 4 mg versus 2.71 for placebo, p=0.012). Multiple event analysis showed 30.7% risk reduction in developing skeletal related events in the Zometa group compared with placebo (p=0.003). The treatment effect in non-small cell lung cancer patients appeared to be smaller than in patients with other solid tumours. Efficacy results are provided in Table 3.

Table 2: Efficacy results (prostate cancer patients receiving hormonal therapy)

<table>
<thead>
<tr>
<th></th>
<th>Any SRE (+TH)</th>
<th>Fractures*</th>
<th>Radiation therapy to bone</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Zometa 4 mg</td>
<td>Placebo</td>
<td>Zometa 4 mg</td>
</tr>
<tr>
<td>N</td>
<td>214</td>
<td>208</td>
<td>214</td>
</tr>
<tr>
<td>Proportion of patients with SREs (%)</td>
<td>38</td>
<td>49</td>
<td>17</td>
</tr>
<tr>
<td>p-value</td>
<td>0.028</td>
<td>0.052</td>
<td>0.119</td>
</tr>
<tr>
<td>Median time to SRE (days)</td>
<td>488</td>
<td>321</td>
<td>NR</td>
</tr>
<tr>
<td>p-value</td>
<td>0.009</td>
<td>0.020</td>
<td>0.055</td>
</tr>
<tr>
<td>Skeletal morbidity rate</td>
<td>0.77</td>
<td>1.47</td>
<td>0.20</td>
</tr>
<tr>
<td>p-value</td>
<td>0.005</td>
<td>0.023</td>
<td>0.060</td>
</tr>
<tr>
<td>Risk reduction of</td>
<td>36</td>
<td>-</td>
<td>NA</td>
</tr>
</tbody>
</table>
In a third phase III randomised, double-blind trial comparing Zometa 4 mg to pamidronate 90 mg, 1,122 adult patients (564 Zometa 4 mg, 558 pamidronate 90 mg) with multiple myeloma or breast cancer with at least one bone lesion were treated with 4 mg Zometa or 90 mg pamidronate every 3 to 4 weeks. Eight patients were excluded from the efficacy analysis because of good clinical practice non-compliance. 606 patients entered the 12-month, double-blind extension phase. Total therapy lasted up to 24 months. The results demonstrated that Zometa 4 mg showed comparable efficacy to 90 mg pamidronate in the prevention of skeletal related events. The multiple event analyses revealed a significant risk reduction of 16 % (p=0.030) in patients treated with Zometa 4 mg. Efficacy results are provided in Table 4.
In clinical trials performed in adult patients with bone metastases or osteolytic lesions, the overall safety profile amongst all treatment groups (zoledronic acid 4 mg, and pamidronate 90 mg and placebo) was similar in types and severity.

Zometa was also studied in a double-blind, randomized, placebo-controlled trial in 228 adult patients with documented bone metastases from breast cancer to evaluate the effect of Zometa on the skeletal related event (SRE) rate ratio, calculated as the total number of SRE events (excluding hypercalcemia and adjusted for prior fracture), divided by the total risk period. Patients received either 4 mg Zometa or placebo every four weeks for one year. Patients were evenly distributed between Zometa-treated and placebo groups.

The SRE rate ratio at one year was 0.61, indicating that treatment with Zometa reduced the rate of occurrence of SREs by 39% compared with placebo (p=0.027). The proportion of patients with at least one SRE (excluding hypercalcemia) was 29.8% in the Zometa-treated group versus 49.6% in the placebo group (p=0.003). Median time to onset of the first SRE was not reached in the Zometa-treated arm at the end of the study and was significantly prolonged compared to placebo (p=0.007). Zometa reduced the risk of SREs by 41% in a multiple event analysis (risk ratio=0.59, p=0.019) compared with placebo.

In the Zometa-treated group, decreases in pain scores from baseline (using the Brief Pain Inventory, BPI) occurred from 4 weeks onwards and at every subsequent time point during the study, while the pain score in the placebo group remained unchanged or increased from baseline (Figure 1). Zometa inhibited the worsening of the analgesic score more than placebo. In addition, 71.8% of Zometa-treated patients versus 63.1% of placebo patients showed improvement or no change in the ECOG performance score at the final observation.

**Figure 1:**
Mean change from baseline in Brief Pain Inventory (BPI) pain scores by treatment group and time on study.
Clinical trial results in the treatment of TIH
Clinical studies in tumour-induced hypercalcemia (TIH) demonstrated that the effect of zoledronic acid is characterised by decreases in serum calcium and urinary calcium excretion. To assess the effects of Zometa versus pamidronate 90 mg, the results of two pivotal multicentre studies in adult patients with TIH were combined in a pre-planned analysis. The results showed that Zometa 4 mg and 8 mg were statistically superior to pamidronate 90 mg for the proportion of complete responders at day 7 and day 10. There was faster normalisation of corrected serum calcium at day 4 for Zometa 8 mg and at day 7 for Zometa 4 mg and 8 mg. The following response rates were observed Table 5:

Table 5: Proportion of complete responders by day in the combined TIH studies

<table>
<thead>
<tr>
<th></th>
<th>Day 4</th>
<th>Day 7</th>
<th>Day 10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zometa 4 mg (N=86)</td>
<td>45.3% (p=0.104)</td>
<td>82.6% (p=0.005)*</td>
<td>88.4% (p=0.002)*</td>
</tr>
<tr>
<td>Zometa 8 mg (N=90)</td>
<td>55.6% (p=0.021)*</td>
<td>83.3% (p=0.010)*</td>
<td>86.7% (p=0.015)*</td>
</tr>
<tr>
<td>Pamidronate 90 mg (N=99)</td>
<td>33.3%</td>
<td>63.6%</td>
<td>69.7%</td>
</tr>
</tbody>
</table>

*p-values denote statistical superiority over pamidronate.

Median time to normocalcaemia was 4 days. By day 10 the response rate was 87 to 88% for the Zometa treatment groups versus 70% for pamidronate 90 mg. Median time to relapse (re-increase of albumin-corrected serum calcium ≥2.9 mmol/L) was 30 to 40 days for patients treated with Zometa versus 17 days for those treated with pamidronate 90 mg. The results showed that both Zometa doses were statistically superior to pamidronate 90 mg for time to relapse. There were no statistically significant differences between the two Zometa doses.
In clinical trials performed in adult patients with tumour-induced hypercalcemia (TIH), the overall safety profile amongst all three treatment groups (zoledronic acid 4 and 8 mg and pamidronate 90 mg) was similar in types and severity.

5.2 Pharmacokinetic properties

Single and multiple 5- and 15-minute infusions of 2, 4, 8 and 16 mg zoledronic acid in 64 patients with bone metastases yielded the following pharmacokinetic data, which were found to be dose independent.

After initiating the infusion of zoledronic acid, the plasma concentrations of drug rapidly increased, achieving their peak at the end of the infusion period, followed by a rapid decline to <10% of peak after 4 hours and <1% of peak after 24 hours, with a subsequent prolonged period of very low concentrations not exceeding 0.1% of peak prior to the second infusion of drug on day 28.

Intravenously administered zoledronic acid is eliminated via a triphasic process: rapid biphasic disappearance from the systemic circulation, with half-lives of $t_{1/2}\alpha 0.24$ and $t_{1/2}\beta 1.87$ hours, followed by a long elimination phase with a terminal elimination half-life of $t_{1/2}\gamma 146$ hours. There was no accumulation of drug in plasma after multiple doses of the drug given every 28 days. Zoledronic acid is not metabolised and is excreted unchanged via the kidney. Over the first 24 hours, $39 \pm 16\%$ of the administered dose is recovered in the urine, while the remainder is principally bound to bone tissue. From the bone tissue it is released very slowly back into the systemic circulation and eliminated via the kidney. The total body clearance is $5.04 \pm 2.5$ L/h, independent of dose, and unaffected by gender, age, race, and body weight. Increasing the infusion time from 5 to 15 minutes caused a 30% decrease in zoledronic acid concentration at the end of the infusion, but had no effect on the area under the plasma concentration versus time curve.

No pharmacokinetic data for zoledronic acid are available in patients with hypercalcemia or in patients with hepatic insufficiency. Zoledronic acid does not inhibit human P450 enzymes in vitro, shows no biotransformation and in animal studies <3% of the administered dose was recovered in the faeces, suggesting no relevant role of liver function in the pharmacokinetics of zoledronic acid.

The renal clearance of zoledronic acid was significantly positively correlated with creatinine clearance, renal clearance representing $75 \pm 33\%$ of the creatinine clearance, which showed a mean of $84 \pm 29$ mL/min (range 22 to 143 mL/min) in the 64 cancer patients studied. Population analysis showed that for a patient with creatinine clearance of 20 mL/min (severe renal impairment), or 50 mL/min (moderate impairment), the corresponding predicted clearance of zoledronic acid would be 37% or 72%, respectively, of that of a patient showing creatinine clearance of 84 mL/min. Only limited pharmacokinetic data are available in patients with severe renal insufficiency (creatinine clearance <30 mL/min). The use of Zometa is not recommended in patients with severe renal impairment (See Warnings and precautions).
Zoledronic acid shows no affinity for the cellular components of blood and plasma protein binding is low (approximately 56%) and independent of the concentration of zoledronic acid.

The three pharmacokinetic studies conducted in cancer patients with bones metastases reveal no effect by gender, race, age (range 38 to 84 years), and body weight on zoledronic acid total clearance.

Preclinical safety data

Acute toxicity
The highest non-lethal single intravenous dose was 10 mg/kg bodyweight in mice and 0.6 mg/kg in rats.

Subchronic and chronic toxicity
Zoledronic acid was well tolerated when administered subcutaneously to rats and intravenously to dogs at doses up to 0.02 mg/kg daily for 4 weeks. Administration of 0.001 mg/kg/day subcutaneously in rats and 0.005 mg/kg/day intravenously in dogs for up to 52 weeks was also well tolerated.

Reproduction toxicity
Zoledronic acid was teratogenic in the rat at subcutaneous doses ≥0.2 mg/kg. Although no teratogenicity or foetotoxicity was observed in the rabbit, maternal toxicity was found.

Mutagenicity and carcinogenic potential
Zoledronic acid was not mutagenic in the mutagenicity tests performed and carcinogenicity testing did not provide any evidence of carcinogenic potential.

Local tolerance
Local tolerance testing in rabbits showed that intravenous administration was well tolerated.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients
Mannitol, sodium citrate, water for injections.

6.2 Incompatibilities
Studies with glass bottles, as well as several types of infusion bags and infusion lines made from polyvinylchloride, polyethylene and polypropylene (pre-filled with 0.9% w/v sodium chloride solution or 5% w/v glucose solution), showed no incompatibility with Zometa.

To avoid potential incompatibilities, Zometa concentrate is to be diluted with 0.9% w/v sodium chloride solution or 5% w/v glucose solution.

Zometa concentrate must not be mixed or come into contact with calcium or other divalent cation-containing infusion solutions, such as Lactated Ringer’s solution, and should be administered as a single intravenous solution in a line separate from all other drugs.
6.3 Shelf life
Zometa 4 mg powder* and Zometa 4 mg/5 mL concentrate for solution for infusion has a shelf life of 3 years.

The Zometa solution (and the stock solution for paediatric use) is stable for 24 hours at 2 to 8°C after further dilution in 100 mL physiological saline or 5% w/v glucose solution. After aseptic reconstitution and dilution, it is preferable to use the reconstituted and diluted product immediately. If not used immediately, the reconstituted solution should be stored at 2 to 8°C. The duration and conditions of storage prior to use are under the healthcare provider’s responsibility. The total time between reconstitution, dilution, storage in a refrigerator at 2 to 8°C and end of administration must not exceed 24 hours.

6.4 Special precautions for storage
No special precautions for storage. Zometa must be kept out of the reach and sight of children.

6.5 Nature and contents of container
Zometa 4 mg/5 mL concentrate for solution for infusion is supplied as packs containing 1 vials. Vial: 5 mL colourless plastic vial container with rubber stopper and flip-off cap.

* Zometa 4 mg powder and solvent for solution for infusion packs of 1 vial and 1 diluent ampoule. Novartis does not supply this presentation of Zometa in New Zealand.

6.6 Special precautions for disposal and other handling
Zometa 4 mg powder for solution* and Zometa 4 mg/5 mL concentrate for solution for infusion is for intravenous use only.

The 4 mg powder* must first be reconstituted in the vial using 5 mL water for injection from the ampoule supplied. Dissolution must be complete before the solution is withdrawn. The amount of reconstituted solution as required is then further diluted with 100 mL of calcium-free infusion solution (0.9% w/v sodium chloride solution or 5% w/v glucose solution).

The 4 mg/5 mL concentrate from one vial or the volume of the concentrate withdrawn as required must be further diluted with 100 mL of calcium-free infusion solution (0.9% w/v sodium chloride solution or 5% w/v glucose solution). If refrigerated, the solution must be allowed to reach room temperature before administration (See also Dosage and administration).

Any unused solution should be discarded. Only clear solution free from particles and discoloration should be used.
7. **MEDICINE SCHEDULE**

Prescription Medicine

8. **SPONSOR**

Te Arai BioFarma Ltd  
PO Box 46205, Herne Bay  
Auckland, 1147

Telephone 0800 TEARAI (832724)

9. **DATE OF FIRST APPROVAL**

22 February 2001

10. **DATE OF REVISION OF THE TEXT**

19 September 2020

**SUMMARY TABLE OF CHANGES**

<table>
<thead>
<tr>
<th>Section Changed</th>
<th>Summary of New Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>8. Sponsor</td>
<td>Section updated to reflect new sponsor.</td>
</tr>
</tbody>
</table>